We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
-15.35%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$95.5M
AUM Growth
-$40.1M
(-30%)
Cap. Flow
-$29.1M
Cap. Flow
% of AUM
-30.5%
Top 10 Holdings %
Top 10 Hldgs %
44.8%
Holding
389
New
183
Increased
50
Reduced
47
Closed
99
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$10.6M |
| 2 |
Baxter International
BAX
|
+$3.81M |
| 3 |
Akebia Therapeutics
AKBA
|
+$2.87M |
| 4 |
OTIC
Otonomy, Inc.
OTIC
|
+$2.46M |
| 5 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$1.81M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$8.82M |
| 2 |
CELG
Celgene Corp
CELG
|
+$6.57M |
| 3 |
DYAX
DYAX CORPORATION
DYAX
|
+$6.35M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$5.44M |
| 5 |
Viatris
VTRS
|
+$2.57M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 49.44% |
| 2 | Miscellaneous | 38.54% |
| 3 | Technology | 4.06% |
| 4 | Consumer Discretionary | 2.5% |
| 5 | Consumer Staples | 1.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
CALL
Pfizer
PFE
$162B
| $8K | 0.01% |
79,050
-127,323
| -62% | -$3.64M |
|
252
PUT
NCR Voyix
VYX
$1.26B
| $8K | 0.01% |
+16,300
| New | +$234K |
|
253
PUT
Verizon
VZ
$208B
| $8K | 0.01% |
15,000
-22,500
| -60% | -$1.13M |
|
|
RDUS
254
CALL
DELISTED
Radius Health, Inc.
RDUS
| $8K | 0.01% |
+29,600
| New | +$1.02M |
|
255
CALL
Clorox
CLX
$11.3B
| $7K | 0.01% |
+34,900
| New | +$4.44M |
|
256
PUT
Heron Therapeutics
HRTX
$65.3M
| $7K | 0.01% |
+2,500
| New | +$49.3K |
|
257
PUT
Kimberly-Clark
KMB
$34.9B
| $7K | 0.01% |
+4,000
| New | +$520K |
|
258
CALL
Kinder Morgan
KMI
$69.9B
| $7K | 0.01% |
15,600
-5,600
| -26% | -$91.6K |
|
259
CALL
Wolfspeed
WOLF
$1.47B
| $7K | 0.01% |
+5,800
| New | +$166K |
|
260
PUT
Infosys
INFY
$47.4B
| $6K | 0.01% |
+17,400
| New | +$152K |
|
261
PUT
Lumen
LUMN
$6.98B
| $6K | 0.01% |
+20,000
| New | +$561K |
|
262
PUT
Rambus
RMBS
$9.27B
| $6K | 0.01% |
+5,200
| New | +$64.5K |
|
|
AKRX
263
DELISTED
Akorn Inc
AKRX
| $6K | 0.01% |
+250
| New | +$6.58K |
|
|
POT
264
CALL
DELISTED
Potash Corp Of Saskatchewan
POT
| $6K | 0.01% |
+35,000
| New | +$589K |
|
|
KITE
265
CALL
DELISTED
Kite Pharma, Inc.
KITE
| $6K | 0.01% |
+20,100
| New | +$974K |
|
266
PUT
Acadia Pharmaceuticals
ACAD
$4.83B
| $5K | 0.01% |
+62,900
| New | +$1.37M |
|
267
PUT
Bristol-Myers Squibb
BMY
$136B
| $5K | 0.01% |
+19,900
| New | +$1.25M |
|
|
268
PUT
Clorox
CLX
$11.3B
| $5K | 0.01% |
+5,000
| New | +$636K |
|
|
K
269
PUT
DELISTED
Kellanova
K
| $5K | 0.01% |
+1,172
| New | +$80.9K |
|
270
PUT
Coca-Cola
KO
$379B
| $5K | 0.01% |
+25,000
| New | +$1.09M |
|
|
271
CALL
Rambus
RMBS
$9.27B
| $5K | 0.01% |
+5,100
| New | +$63.2K |
|
|
AEGR
272
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
| $5K | 0.01% |
67,900
| – | – |
|
|
ADT
273
PUT
DELISTED
ADT Corp
ADT
| $5K | 0.01% |
+18,100
| New | +$635K |
|
274
PUT
Applied Materials
AMAT
$361B
| $4K | ﹤0.01% |
+8,100
| New | +$148K |
|
275
PUT
Cadence Design Systems
CDNS
$80.6B
| $4K | ﹤0.01% |
+25,000
| New | +$524K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q1 2016 Portfolio in Review
As of Q1 2016, FT Options held 389 positions worth $95.5M, down 30% from $136M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
FT Options withdrew a net $29.1M in Q1 2016, closing 99 positions and reducing 47 holdings. Its most notable exit was Celgene Corp, an estimated $6.57M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 49% of assets, up from 43% a quarter earlier, followed by Miscellaneous and Technology.
Against the trend, FT Options opened a new position in Baxter International worth $4.11M.
- FT Options's largest Q1 2016 buy was Baxter International: 100,000 shares worth $4.11M.
- FT Options added most to Regeneron Pharmaceuticals in Q1 2016, an estimated $10.6M increase.
- FT Options's biggest Q1 2016 reduction was Gilead Sciences, cutting an estimated $8.82M.
- FT Options fully exited Celgene Corp in Q1 2016, selling an estimated $6.57M.
- FT Options's ten largest holdings make up 45% of its $95.5M portfolio in Q1 2016.
- FT Options opened 183 new positions and closed 99 in Q1 2016.
- FT Options's portfolio value fell 30% quarter-over-quarter to $95.5M.
Based on FT Options's 13F filing for Q1 2016, filed 9 May 2016.